Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    3
    ...
ATC Name B/G Ingredients Dosage Form Price
B03AB ENRICH N G Iron trivalent (hydroxide polymaltose complex) - 156.25mg/5ml Syrup 279,519 L.L
B03AB05 ENRICH N G Iron trivalent (hydroxide polymaltose complex) - 50mg/ml 50mg/ml Drops 459,594 L.L
B03AD EURO-FER CF G Folic acid - 0.5mg, Vitamin C - 200mg, Ferrous fumarate - 300mg Capsule 706,861 L.L
B03AE02 ELEVIT PRONATAL G Vitamin A, palmitate - 1080mcg, Vitamin B1 - 1.6mg, Vitamin B2 - 1.8mg, Vitamin B6 - 2.6mg, Vitamin B12 - 4mcg, Vitamin C - 100mg, Vitamin D3 - 12.5mcg, Vitamin E - 15mg, Biotin - 0.2mg, Calcium Pantothenate - 10mg, Folic acid - 0.8mg, Nicotinamide - 19mg, Calcium - 125mg, Magnesium - 100mg, Phosphorous - 125mg, Iron - 60mg, Copper - 1mg, Manganese - 1mg, Zinc - 7.5mg Tablet, film coated 893,655 L.L
B03XA01 EPOMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 2000UI/ml 2000UI/ml Injectable solution 7,849,606 L.L
B03XA01 EPOMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 4000UI/ml 4000UI/ml Injectable solution 1,243,054 L.L
B03XA01 EPOTEX 4000 BENTA BioTech Erythropoietin recombinant human (Epoetin alfa) - 4,000IU 4,000IU Injectable solution 1,209,458 L.L
B03XA01 EPOTEX 4000 BENTA BioTech Erythropoietin recombinant human (Epoetin alfa) - 4,000IU 4,000IU Injectable solution 5,488,046 L.L
B03XA01 EPOMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 10000UI/ml 10000UI/ml Injectable solution 2,486,109 L.L
B03XA01 EPOTIN BioTech Erythropoietin recombinant human (Epoetin alfa) - 2,000IU 2,000IU Injectable solution 9,206,440 L.L
B03XA01 EPOTIN BioTech Erythropoietin recombinant human (Epoetin alfa) - 4,000IU/ml 4,000IU/ml Injectable solution 11,317,795 L.L
B03XA01 EPOMAX BioTech Erythropoietin recombinant human (Epoetin alfa) - 4000UI/ml 4000UI/ml Injectable solution L.L
B05BB02 ELECTROLYE 67 G Calcium gluconate - 0.10g/100ml, Potassium chloride - 0.075g/100ml, Sodium chloride - 0.30g/100ml, Dextrose, H2O - 5.0g/100ml Injectable solution 165,727 L.L
B05DA EXTRANEAL (ICODEXTRIN 7.5%) TWIN BAG B Sodium lactate - 4.5g/l, Magnesium Chloride - 0.051g/l, Calcium chloride - 0.257g/l, Sodium chloride - 5.4g/l, Icodextrin - 75.0 g/l Injectable solution 1,998,025 L.L
B05DA EXTRANEAL (ICODEXTRIN 7.5%) SINGLE BAG B Sodium lactate - 4.5g/l, Magnesium Chloride - 0.051g/l, Calcium chloride - 0.257g/l, Sodium chloride - 5.4g/l, Icodextrin - 75.0 g/l Injectable solution 1,998,025 L.L
C01CA03 EPINORD G Noradrenaline (tartrate) - 8mg/4ml 8mg/4ml Injectable solution 2,751,678 L.L
C01CA26 EPHEDRINE AGUETTANT G Ephedrine HCl - 30mg/ml 30mg/ml Injectable solution 614,136 L.L
C01CA26 EPHEDRINE RENAUDIN G Ephedrine HCl - 30mg/ml 3% Injectable solution 693,423 L.L
C01CA26 EPHEDRINE AGUETTANT G Ephedrine HCl - 3mg/ml 3mg/ml Injectable solution 7,827,491 L.L
C03AA03 ESIDREX B Hydrochlorothiazide - 25mg 25mg Tablet 380,115 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 25mg 25mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 25mg 25mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 25mg 25mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE BIOGARAN G Eplerenone - 25mg 25mg Tablet, coated 1,849,127 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 50mg 50mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 50mg 50mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 50mg 50mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE BIOGARAN G Eplerenone - 50mg 50mg Tablet, coated 1,849,127 L.L
C09BB06 ENEAS G Enalapril maleate - 10mg, Nitrendipine - 20mg Tablet 2,009,045 L.L
C09CA09 EDARBI B Azilsartan medoxomil - 40mg 40mg Tablet 1,846,440 L.L
    3
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025